Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VX-828 combinations in cystic fibrosis
NL-OMON61184Phase 2Not yet recruiting
- Sponsor
- Vertex Pharmaceuticals
- Start
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of VX-828, deutivacaftor, tezacaftor in cystic fibrosis (CF), sponsored by Vertex Pharmaceuticals. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
VX-828deutivacaftortezacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NL-OMON61184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61184.